PSN602

PSN602 is a small molecule agonist of the G protein-coupled receptor 119 (GPR119), originally developed for the treatment of metabolic disorders such as type 2 diabetes and obesity. GPR119 is a lipid-sensing receptor predominantly expressed in pancreatic beta cells and enteroendocrine L-cells of the gastrointestinal tract. By activating this receptor, PSN602 stimulates glucose-dependent insulin secretion and promotes the release of incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This dual mechanism of action was intended to improve glycemic control while potentially offering weight management benefits. The drug was developed by Prosidion, a subsidiary of OSI Pharmaceuticals; however, clinical development appears to have ceased following the acquisition of OSI Pharmaceuticals by Astellas Pharma and the subsequent closure of the Prosidion research unit.